

ARHB Antibody (Center)
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP12264c

Specification

ARHB Antibody (Center) - Product Information

Application	WB, IHC-P,E
Primary Accession	P62745
Other Accession	P62747 , P62746 , O3ZBW5 , NP_004031.1
Reactivity	Human
Predicted	Bovine, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	22123
Antigen Region	104-137

ARHB Antibody (Center) - Additional Information

Gene ID 388

Other Names

Rho-related GTP-binding protein RhoB, Rho cDNA clone 6, h6, RHOB, ARH6, ARHB

Target/Specificity

This ARHB antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 104-137 amino acids from the Central region of human ARHB.

Dilution

WB~~1:4000
IHC-P~~1:10~50

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

ARHB Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

ARHB Antibody (Center) - Protein Information

Name RHOB

Synonyms ARH6, ARHB

Function Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF receptor from late endosomes to lysosomes. Also required for stability and nuclear trafficking of AKT1/AKT which promotes endothelial cell survival during vascular development. Serves as a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Required for genotoxic stress-induced cell death in breast cancer cells.

Cellular Location


Late endosome membrane; Lipid-anchor. Cell membrane; Lipid-anchor. Nucleus. Cleavage furrow. Note=Late endosomal membrane (geranylgeranylated form). Plasma membrane (farnesylated form). Also detected at the nuclear margin and in the nucleus Translocates to the equatorial region before furrow formation in a ECT2-dependent manner

ARHB Antibody (Center) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

ARHB Antibody (Center) - Images



Anti-ARHB Antibody (Center) at 1:4000 dilution + human brain lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 22 kDa Blocking/Dilution buffer: 5% NFDN/TBST.



ARHB Antibody (Center) (Cat. #AP12264c) immunohistochemistry analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of ARHB Antibody (Center) for immunohistochemistry. Clinical relevance has not been evaluated.

ARHB Antibody (Center) - Background

ARHB mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF receptor from late endosomes to lysosomes. Also required for stability and nuclear trafficking of AKT1/AKT which promotes endothelial cell survival during vascular development.

ARHB Antibody (Center) - References

- Adly, M.A., et al. *J. Cutan. Pathol.* 37(7):751-757(2010)
- Connolly, E.C., et al. *Mol. Cancer Res.* 8(5):691-700(2010)
- Zintzaras, E., et al. *Am. J. Epidemiol.* 171(8):851-858(2010)
- Kim, C.H., et al. *Biochem. Biophys. Res. Commun.* 391(2):1182-1186(2010)
- Takefuji, M., et al. *J. Hum. Genet.* 55(1):42-49(2010)